Clinical stage cell therapy company Chimeric Therapeutics (ASX:CHM) has dosed the first patient in the CHM 0201 (CORE NK) + Vactoserib clinical trial.
The company says this is the first ever clinical trial to assess NK cells in combination with Vactoserib in patients with advanced colorectal and blood cancers.
Furthermore, the company reports the CHM 0201 platform is a potential ‘best in class’ NK cell platform of ex-vivo expanded non-HLA-matched universal donor NK cells.
The platform was previously studied in a phase one clinical trial that established safety with no graft versus host disease (GvHD), 28-day NK cell persistence and an encouraging early efficacy signal, particularly in blood cancers where all patients achieve disease control. It also notes 1 patient achieved a complete response that was sustained for over 15 months at the time of study publication.
Chimeric reports the objective of this new phase one B study is to build upon the clinical responses seen in the initial CORE NK phase one A clinical trial by adding Vactoserib, an oral TGF-ß receptor inhibitor that can potentially disrupt the TGF-ß signalling pathway.
This new trial is being led by US Seidman oncologist J. Eva Selfridge, and Assistant Professor at Case Western Reserve University School of Medicine in Ohio, and is designed to treat 12 patients with either locally advanced and metastatic colorectal cancer, or relapsed and refractory blood cancers.
“Dosing of the first patient in this trial is a meaningful step towards realising the potential of CHM 0201 in providing better options for treatment and care to these patients”
Commenting on the new clinical trial, Chimeric Chief Executive Officer (CEO) and Managing Director Jennifer Chow said: “Both advanced colorectal cancer and acute myeloid leukaemia continue to be defined by high unmet needs in the relapse-refractory setting.
Dosing of the first patient in this trial is a meaningful step towards realising the potential of CHM 0201 in providing better options for treatment and care to these patients.”
Chimeric notes the phase one B trial is currently funded without financial support from the company.
Chimeric Therapeutics is a clinical stage therapy company focused on bringing the promise of cell therapy to life for more patients with cancer. The company believes cellular therapies have the promise to cure cancer, not just delay disease progression.
Its portfolio of cell therapy products include CHM 1101, a CART therapy designed for the treatment of patients with solid tumours, CHM 2101 wich is a CAR T cell therapy designed for gastrointestinal cancers, and CHM 0201, a NK cell platform aiming to treat blood cancer and solid tumours.
